33 results about "Cutaneous Disorders" patented technology

A new method of treating a skin disease or condition in a human subject caused by a parasite, particularly Demodex mite infestations that result in demodicosis, with moxidectin. The demodicosis is typically Demodex blepharitis.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The present invention relates to a pharmaceutical composition, quasi-drug composition, or cosmetic composition for the prevention, improvement, or treatment of skin diseases, comprising as an active ingredient a tubulin inhibitor and one or more compounds selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof. The combination therapy of the present invention can be used as an active ingredient that simultaneously exhibits activities such as skin moisturizing, whitening, wrinkle improvement, acne relief, skin barrier strengthening, or keratinocyte differentiation, along with the prevention, treatment, or improvement of skin diseases.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

There is provided a compound of formula I, X-Y (I) wherein: Y comprises a peptide fragment of formula IV, [Ala] m-[Lys-V] n-Lys-V (IV) wherein m represents 0 or 1, n represents the integer 0, 1, 2, 3 or 4, and each V independently represents a sequence of 2 to 4 amino acids wherein the amino acids are selected from one or more of the group consisting of Lys, Pro, Hyp, diHyp, Thr, pThr, DOPA, Tyr and Ser; and X represents at least one optional substituent selected from the group consisting of: (i) a lipid selected from the group consisting of vitamin A, vitamin E, cholesterol and fatty acids comprising one or more carboxylic acid groups, 1 to 50 carbons and / or one or more cyclic rings, said lipids being linear or branched, saturated or unsaturated with between 1 and 10 carbon-carbon double bonds and / or substituted with between 1 and 10-OH groups, or a derivative of any of these lipids; and / or (ii) a non-steroidal anti-inflammatory agent, which compounds may be used in medicine, including as pharmaceutical excipients, adhesives and film-forming materials, and / or may be used in the treatment of conditions characterized by inflammation, including wounds, burns and mucosal disorders such as skin diseases, oral diseases, gynecological diseases and IBD.

The invention discloses a handheld nitric oxide treatment device for preventing and treating skin diseases. The rotating gliding arc discharge technology is adopted, and a high-density local energy field is formed in air, so that nitrogen and oxygen molecules efficiently react to generate NO and NO2. NO gas flow with stable concentration can be generated under the condition of low-voltage power supply, and in-situ treatment of the skin surface is realized. The USB PD standard power supply is applied to the NO treatment device for the first time, so that the energy required by discharge driving is ensured, and the safety risk of high-voltage direct supply is avoided. In addition, a discharge module, an airflow channel and a heat dissipation structure in the device adopt an integrated layout, and triple cooperation of airflow driving, discharge generation and cooling is realized. The adjustability of the proportion of the active components is realized by controlling the discharge power and the airflow speed, and the treatment effect and the biological safety can be both considered. The invention can be widely applied to the scenes of home nursing, adjuvant therapy of skin diseases, wound disinfection, post-medical and post-art recovery and the like.

Disclosed are methods for treating an autoimmune and / or an inflammatory disease, disorder, or condition, including a skin disease, disorder, or condition comprising orally administering a prodrug of itaconate, 4-methyl itaconate, or 1-methyl itaconate to a subject in need of treatment thereof.

The present invention relates to a pharmaceutical composition for preventing or treating skin diseases caused by radiation irradiation, comprising darapladib or a pharmaceutically acceptable salt thereof as an active ingredient. Darapladib improves damaged skin due to radiation irradiation, such as maintaining the water loss amount, water content level and pH level of damaged skin due to radiation irradiation, and recovering skin thickness and adipocyte area, and thus can be effectively used as a composition for preventing, treating or ameliorating skin diseases caused by radiation irradiation.

Described herein is a method of reducing a sign or symptom of a dermal disorder in a subject in need of treatment for the dermal disorder by topically applying a topical silk fibroin composition once or more daily to the site of the dermal disorder, wherein the silk fibroin formulation includes no additional dermal therapeutic agents. Also included are methods of reducing topical steroid use in in a subject in need of treatment for a dermal disorder.

The present invention relates to a male / female groin care dryer. The male / female groin care dryer is provided on the walls or lockers of shower facilities in gyms, public baths, golf courses, swimming pools and the like so as to be conveniently usable by both men and women in a way that the male / female groin care dryer is used to dry the Y-zone (groin) after drying off with towels post-shower, thereby being a hygiene product capable of preventing skin diseases related to the groin. The male / female groin care dryer has a simple structure, can be manufactured at low costs and at low unit price through mass production so as to reduce the burden of purchasing costs, and thus can be widely distributed and used.

The present invention relates to a cooling garment, and more particularly, to a cooling garment that, when simply worn on the body of a worker in a special environment such as a construction site, industrial facilities, agriculture, etc., prevents heat stroke, dehydration, fatigue, and other health problems caused by an increase in body temperature in summer, prevents discomfort and skin diseases caused by the wetting of a work garment by sweat, and not only that, maintains a comfortable environment even in hot weather in daily life, sports, or outdoor activities, and further, prevents a decrease in concentration and fatigue accumulation caused by a long-term increase in body temperature, thereby ensuring the safety and physical activity efficiency of a user.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

The invention discloses a double-layer microneedle delivery system for acne treatment as well as a preparation method and application of the double-layer microneedle delivery system, and belongs to the technical field of biomedical materials and infectious skin disease treatment. According to the double-layer microneedle delivery system, a copper-tannic acid compound is packaged in a needle tip layer, and probiotic outer membrane vesicles are loaded on a backing layer, so that an intelligent delivery platform with a time-space graded release characteristic is constructed. According to the double-layer structural design, the technical problem of multi-component sequential release is solved, the organic integration of antibacterial, anti-inflammatory and repairing functions is realized, and a new treatment strategy which is efficient, low in side effect and capable of preventing scar formation is provided for acne and other complex skin inflammatory diseases.

Pharmaceutical compositions of alpha-lipoic acid and / or methylsulfonylmethane (MSM) and magnesium salts, useful for the treatment, prevention, or reduction of the severity of viral infections and / or skin diseases, are provided herein. Methods for preparing the pharmaceutical compositions and methods for using the pharmaceutical compositions in therapeutic treatments are also provided.

The invention discloses indole-3-lactic acid loaded beta-glucan modified PLGA nanoparticles, and relates to the technical field of nano-drug delivery and skin disease treatment, and the indole-3-lactic acid loaded beta-glucan modified PLGA nanoparticles comprise the following steps: 1, preparing a solution; preparing a solution 1 and a solution 2; 2, emulsifying and forming nano-particles; dropwise adding the solution 2 into the continuously stirred solution 1; adding deionized water while continuously stirring, and carrying out ultrasonic treatment for 10-20 minutes to promote the volatilization of dichloromethane DCM; performing centrifugal washing, removing polyvinylpyrrolidone (PVP) and residual solvent, and performing vacuum drying to obtain polylactic acid-glycolic acid copolymer (PLGA) nanoparticles; step 3, beta-glucan modification: preparing a beta-glucan solution with a concentration of 2 mg / mL according to a mass ratio of 1: 1, and adding a PLGA (at) drug NPs suspension; performing ultrasonic dispersion for 30 minutes and stirring overnight; and carrying out centrifugal washing to remove uncombined beta-glucan, so as to obtain a final product, namely the PLGA (at) drg-beta-glucan nano-particles.

Novel retinamides with unique properties and biological activities, including inhibition of retinoic acid metabolism and modulation of Mnk1 / 2-eIF4E and androgen receptor (AR) signaling pathways, are synthesized and developed. The novel retinamides are capable of effecting treatment of a variety of dermatological conditions while limiting adverse side effects.

The invention belongs to the technical field of superoxide dismutase preparation, and particularly relates to a preparation method of SOD condensate stock solution for inflammation relief, which comprises the following steps: SOD enzyme source raw material selection and pretreatment: recombinant human Cu / Zn-SOD is selected as a preferred enzyme source, and the specific activity of the recombinant human Cu / Zn-SOD is greater than or equal to 6000 U / mg protein; or selecting a plant source such as spinach and garlic, or a microbial source such as SOD fermented by bacillus subtilis as an alternative enzyme source; gel filtration chromatography (GFC) is adopted for purifying the selected SOD, impure protein and endotoxin are removed, and the purity is larger than or equal to 95%; the preparation method of the SOD condensate stock solution for relieving inflammation has high activity and stability: dissolved oxygen (less than or equal to 2mg / L) in water is reduced through vacuum low-temperature condensation (0-5 DEG C), and SOD oxidation inactivation is reduced; recombinant human source SOD or plant / microorganism source SOD is selected according to different requirements, and the requirements of multiple scenes such as adjuvant therapy of inflammatory skin diseases, anti-inflammatory skin care products and the like can be met through fine adjustment of technological parameters.

Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated dermatological diseases or conditions.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

We provide horse health promotion equipment that can help horses recover from fatigue and also help prevent skin diseases. [Solution] The horse health promotion device 100 comprises a first light source 3 that emits near-infrared and red light, a second light source 4 that emits ultraviolet UVA and UVB light, and a support member 40 that directs the light emitted from the first light source and the light rays from the second light source toward the horse's body. The support member is either a ceiling light 20 installed in the horse's stable or a horse blanket that can be attached to and removed from the horse's body. By directing near-infrared and red light toward the horse's body, the horse's body is warmed and its health is promoted, and by irradiating with ultraviolet light, the horse's body can be sterilized and disinfected. This allows the horse to recover from fatigue and heal skin diseases.

Disclosed herein compositions of polysaccharides chemically cross-linked by aromatic dialdehydes. The compositions may be in form of polymeric sheets for a variety of applications. Disclosed also nano-sized particles comprising the polysaccharide chemically cross-linked by aromatic dialdehydes. The nano-sized particles may further comprise lipids and surfactants. Intranasal delivery of the nano-sized particles enables delivery of biologically active agents into the brain. Topical and transdermal delivery of the nano-sized particles enables delivery of biologically active agents for treatment of systemic or dermatological disorders. Methods of manufacturing and uses of the compositions are also disclosed.

The invention belongs to the technical field of medicines for treating inflammatory skin diseases, and discloses application of kinsenoside in preparation of medicines for treating skin inflammatory diseases, the structural formula of kinsenoside is shown in the specification, and kinsenoside can be particularly used for preparing medicines for treating psoriasis. According to the application, the kinsenoside is applied to the preparation of the medicine for treating the skin inflammatory diseases, particularly the medicine for treating the psoriasis for the first time, the kinsenoside can up-regulate arachidonate 15-lipoxygenase (ALOX15) in the skin so as to intervene the psoriasis, and a candidate medicine is provided for clinically developing natural products for treating the skin inflammatory diseases including the psoriasis.

Abstract Methods of treating skin lesions using cantharidin as well as associated compositions treatment regimens, kits, devices and systems are provided. Abstract

The invention relates to bi-crosslinking hydrogel as well as a preparation method and application thereof, and belongs to the technical field of polymer functional materials. According to the bi-crosslinked hydrogel, phenylboronic acid grafted carboxymethyl chitosan serves as a core skeleton, a first crosslinked network is formed by boric acid ester bonds and procyanidine, and a second crosslinked network is formed by Schiff base bonds and oxidized arabinogalactan. A composite network structure is constructed by integrating chemical crosslinking and physical crosslinking, the mechanical property, self-repairing property and environmental response stability of the hydrogel material are remarkably improved, and efficient drug loading and releasing are achieved through physical adsorption and chemical bonding of a three-dimensional network; besides, oxidized ferulic acid nanoparticles are loaded in the hydrogel, so that the oxidation resistance and the antibacterial effect are further improved, and the hydrogel has a wide application prospect in treatment of inflammatory and infectious skin diseases such as chronic refractory wounds and the like.

The application discloses a substituted meta-triphenyl compound, a pharmaceutical composition thereof and application, and the substituted meta-triphenyl compound is shown as formula (I). The compound can be used for treating or preventing skin diseases.

The present disclosure relates to pharmaceutical compositions, including topical formulations thereof, comprising a serine / arginine-rich splicing factor 3 (SRSF3) inhibitor and uses thereof in methods of treating or preventing squamous cell carcinoma and other cutaneous diseases and disorders.

The invention discloses a traditional Chinese medicine composition for preventing and / or treating inflammatory skin diseases and application thereof.The traditional Chinese medicine composition is composed of Sichuan rhizoma coptidis, Sichuan cortex phellodendri, scutellaria baicalensis and betel nuts, the Sichuan cortex phellodendri serves as a monarch drug to clear away heat and dry dampness, purge fire to remove toxin and astringe dampness and heal sores, the Sichuan rhizoma coptidis, the scutellaria baicalensis and the betel nuts serve as ministerial drugs, the Sichuan rhizoma coptidis purges fire to remove toxin and directly fold heat toxin, and the Sichuan cortex phellodendri and the betel nuts serve as monarch drugs. Baikal skullcap root is used for clearing heat, drying dampness, cooling blood and detoxifying, rhizoma coptidis from Sichuan of China and baikal skullcap root are cooperated with monarch drugs to strengthen the effects of eliminating dampness and detoxifying, betel nut is used for promoting the circulation of qi, promoting urination, helping rhizoma coptidis from Sichuan of China, baikal skullcap root and golden cypress to dredge damp evil and relieve swelling and exudation, and the pungent and divergent properties of betel nut can slightly prevent excessive stasis of drug properties, facilitate penetration of drug properties to skin, kill parasites to relieve itching and directly relieve itching caused by insect epidemic. According to the traditional Chinese medicine composition, only four medicines are combined, the composition is simple, all the medicines have a synergistic effect, damp-heat toxin can be attacked by drying, clearing, benefiting and killing, pathogenic factors can be strongly removed, and skin diseases such as acute eczema, impetigo and contact dermatitis can be effectively treated.

The invention provides that the expression and / or activity of metal ion transporter, such as a Ca2+ / Mn2+ transporter and secretory pathway calcium ATPase 1 (SPCA1) or SPCA2 is associated with the restoration and conservation of Golgi integrity in cells, and with the restoration of Golgi ion concentrations. Provided herein are methods of restoring or maintaining Golgi integrity and methods of modulating Golgi ion concentration in a cell including increasing the expression and / or activity of a metal ion transporter such as SPCA1 or SPCA2 in the cell. The invention further provides methods of treating diseases including neurodegenerative disease and Hailey Hailey disease including increasing the expression and / or activity of a metal ion transporter such as SPCA1 or SPCA2 protein in cells to restore or maintain Golgi integrity and Golgi ion concentration in the cell.